Novo Nordisk to Invest Over US$505 million (€400 million) to Expand Athlone Manufacturing Facility in Ireland
Tuesday, March 03, 2026
Novo Nordisk has announced an investment of €432 million (approximately $505 million or DKK 3.2 billion) to expand its manufacturing facility in Monksland, Athlone, Ireland.
The Athlone site is a tabletting facility and will provide additional production capacity for the company’s current and future GLP-1 treatments. The investment represents a significant strategic step and strengthens the company’s long-term presence in Ireland, while supporting global healthcare demand.
The expansion will involve upgrading and retrofitting the existing facility. It will enhance manufacturing capabilities for oral products, increase supply capacity, and position Ireland as an important hub for serving markets outside the United States. The development is expected to strengthen production of oral GLP-1 medicines to meet rising global demand.
The site currently employs 260 people, who will continue focusing on delivering high-quality oral treatments in an efficient and environmentally responsible manner. The overall project covers 45 acres (18 hectares) and is expected to create up to 500 construction jobs during the development phase.
Construction has already begun and is scheduled for phased completion between late 2027 and 2028.
Source: novonordisk.com
